As the CDC revises its COVID-19 vaccination recommendations, confusion reigns over who can get vaccinated this fall. Health experts and patients face barriers and uncertainty in access to vaccines.
A new regulator confirmation links Ozempic to a rare eye condition, NAION, affecting diabetes patients. This revelation raises concerns about potential blindness risks associated with semaglutide. Discover the implications for users.
In a controversial decision, the Trump administration has rescinded guidance protecting pregnant patients in medical emergencies from being denied care due to state abortion bans, raising concerns among healthcare providers and advocates.
The Trump administration's decision to revoke guidance requiring hospitals to provide emergency abortions raises serious concerns for women's health, especially in states with strict abortion bans. Advocates warn this could lead to dangerous consequences for pregnant women in medical emergencies.
In a revealing interview, Dr. Marty Makary, FDA commissioner, raises concerns over past Covid-19 vaccine recommendations, emphasizing the importance of discussions between patients and their doctors.
A landmark study shows that a structured exercise program significantly improves survival rates and reduces cancer recurrence in colon cancer patients, urging healthcare systems to adopt exercise coaching as a standard care.
A groundbreaking study reveals that exercise can reduce cancer patients' risk of death by 37% and recurrence by 28%, proving it's even more effective than many drugs. This landmark trial could reshape health guidelines globally.
A groundbreaking study shows that GLP-1 diabetes drugs may reduce the risk of obesity-related cancers by 7% compared to DPP-4 inhibitors, particularly in women. Discover the implications for diabetes treatment!
A groundbreaking blood test cleared by the FDA offers a new way to diagnose Alzheimer's disease, improving accuracy and accessibility for millions. Experts believe this innovation will enhance patient care and early intervention.
The FDA has approved Lumipulse, the first blood test for diagnosing Alzheimer’s, offering a simpler and less invasive option compared to traditional methods like PET scans. Experts believe this could revolutionize care and research.
